An ongoing, single-arm study of patients with thyroid nodules, showed that the mean percent of volume reduction at three months and at 12 months after echotherapy were 47.4% ± 20.8% and 55.5% ± 28.4%, respectively, in group 1 (only one session) and were 24.2% ± 15.8% and 46.0% ± 22.0%, respectively, in group 2 (two sessions). (Abstract ID: CA-51)
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Ad Statistics
Times Displayed: 43955
Times Visited: 1336 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402
Back to HCB News
